<DOC>
	<DOCNO>NCT00847210</DOCNO>
	<brief_summary>The purpose study asses pharmacokinetics safety dexlansoprazole modify release ( MR ) , daily ( QD ) , adolescent subject ( age 12-17 year old ) Symptomatic Gastroesophageal Reflux Disease .</brief_summary>
	<brief_title>Pharmacokinetic Safety Dexlansoprazole Adolescents With Gastroesophageal Reflux Disease</brief_title>
	<detailed_description>Gastroesophageal reflux disease condition multifactorial etiology result reflux gastric content esophagus low esophageal sphincter . The prevalence Gastroesophageal reflux disease pediatric population become increasingly recognize document . It chronic disease persist adulthood symptom old child adolescent similar see adult . The prevalence gastroesophageal reflux disease increase age , 2.5 % child age 3 9 year , 8.5 % age 10 17 year . Younger child generally present extra-esophageal manifestation , regurgitation , epigastric pain , old child adolescent typically present adult-type gastroesophageal reflux disease symptom heartburn regurgitation . Treatment gastroesophageal reflux disease aim alleviate symptom heal esophageal inflammation . This study evaluate pharmacokinetics safety dexlansoprazole MR pediatric population ( age 12-17 ) determine pharmacokinetic profile similar adult give dose .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>Body weight great equal 30 kg . Females childbearing potential sexually active must agree use acceptable form contraception , neither pregnant lactating Screening throughout duration study . Must estimate creatinine clearance great equal 80 mL/minute determine CockcroftGault formula . Participants take prescription nonprescription proton pump inhibitor , histamine receptor antagonist ( except cimetidine ) , sucralfate , antacid regular require basis must agree discontinue usage throughout study . Must history gastroesophageal reflux disease symptom , document physician , least 2 month prior Screening currently symptomatic . Must able swallow study drug capsule must able ingest study drug granule sprinkle 1 tablespoon applesauce . Has evidence current cardiovascular , central nervous system , hepatic , hematopoietic , renal , metabolic dysfunction , serious allergy , asthma , allergic skin rash . Has find his/her medical history , physical examination , safety clinical laboratory test give reasonable suspicion disease might interfere conduct trial would contraindicate take dexlansoprazole MR similar drug class . Has know hypersensitivity proton pump inhibitor component formulation dexlansoprazole MR ( see current version Investigator Brochures ) . Has history malignant disease . Has positive test result hepatitis B surface antigen , hepatitis C virus antibody . Has know history infection human immunodeficiency virus . Has donate lose great equal 300 mL blood volume , undergone plasmapheresis , transfusion blood product within 90 day prior first dose study drug . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication . Has consume grapefruit grapefruit juice within 14 day prior first dose study drug unwilling agree abstain grapefruit grapefruit juice participate study . Has history alcohol abuse illegal drug use drug abuse past , test positive alcohol drug abuse initial Screening Visit Day 1 unwilling agree abstain alcohol drug throughout study . Has use product contain nicotine within 90 day prior first dose study drug positive cotinine screen initial Screening Visit Day 1 unwilling agree abstain throughout study . Has participate study investigational agent ( include dose follow ) within 30 day prior first dose study drug . Has initial Screening Visit Day 1 laboratory value principal investigator considers clinically significant . Participant determine CYP2C19 isozyme poor metabolizer ( ie , genotyped homozygous nonwild type ) . Is unlikely comply protocol unsuitable reason per opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Esophageal Reflux</keyword>
	<keyword>Gastro-Esophageal Reflux</keyword>
	<keyword>Gastroesophageal Reflux Disease</keyword>
	<keyword>GERD</keyword>
	<keyword>Regurgitation , Gastric</keyword>
	<keyword>Heartburn</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Adolescent</keyword>
</DOC>